Hospital performance for pharmacologic venous thromboembolism prophylaxis and rate of venous thromboembolism: A cohort study

JAMA Internal Medicine

Volumn 174, Issue 10, 2014, Pages 1577-1584

  Flanders, Scott A ^a,b   Greene, M Todd ^a,b   Grant, Paul ^a,b   Kaatz, Scott ^a,c   Paje, David ^a,d   Lee, Bobby ^a,e   Barron, James ^a,f   Chopra, Vineet ^a,b,g   Share, David ^h   Bernstein, Steven J ^a,b,g  

^a Michigan Hospital Medicine Safety Consortium   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c HURLEY MEDICAL CENTER   (United States)

^d HENRY FORD HEALTH SYSTEM   (United States)

^e Oakwood Health System   (United States)

^f SPECTRUM HEALTH   (United States)

^g VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^h Blue Cross Blue Shield of Michigan Cardiovascular Consortium   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; ANTICOAGULANT AGENT;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEALTH CARE QUALITY; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTICENTER STUDY (TOPIC); RETROSPECTIVE STUDY; RISK ASSESSMENT; TELEPHONE INTERVIEW; THROMBOSIS PREVENTION; TREATMENT OUTCOME; UNITED STATES; VENOUS THROMBOEMBOLISM; CLINICAL TRIAL; COMPARATIVE STUDY; HOSPITAL; INCIDENCE; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; PRIMARY PREVENTION; PROCEDURES; RISK; RISK FACTOR; STANDARDS; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; ANTICOAGULANTS; FEMALE; HOSPITALS; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MICHIGAN; MIDDLE AGED; ODDS RATIO; PATIENT ADMISSION; PRIMARY PREVENTION; RETROSPECTIVE STUDIES; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84907997115     PISSN: 21686106     EISSN: 21686114     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.3384     Document Type: Article

References (32)

1. Bump GM, Dandu M, Kaufman SR, Shojania KG, Flanders SA. How complete is the evidence for thromboembolism prophylaxis in general medicine patients? ameta-analysis of randomized controlled trials. J HospMed. 2009;4(5):289-297.
2. Dentali F, Douketis JD, Gianni M, LimW, Crowther MA.Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med. 2007;146(4):278-288.
3. Wein L, Wein S, Haas SJ, Shaw J, Krum H. Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: ameta-analysis of randomized controlled trials. Arch Intern Med. 2007;167(14):1476-1486.
4. Lederle FA, Zylla D, MacDonald R, Wilt TJ. Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: a background review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2011;155(9):602-615.
5. Cohen AT, Tapson VF, Bergmann JF, et al; ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371(9610):387-394.
6. Rothberg MB, LahtiM, Pekow PS, Lindenauer PK. Venous thromboembolism prophylaxis among medical patients at US hospitals. J Gen Intern Med. 2010;25(6):489-494.
7. The Joint Commission. Core measure sets. 2013. http://www.jointcommission.org/core-measure-sets.aspx. Accessed September 19, 2013.
8. National Quality Forum. National voluntary consensus standards for prevention and care of venous thromboembolism: policy, preferred practices, and initial performance measures. 2006. http://www.qualityforum.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=22040. Accessed September 19, 2013.
9. Galson S. The Surgeon General's call to action to prevent deep vein thrombosis and pulmonary embolism. 2008. http://www.surgeongeneral.gov/library/calls. Accessed September 19, 2013.
10. Agency for Healthcare Research and Quality. Preventing hospital-acquired venous thromboembolism: a guide for effective quality improvement. 2008. http://www.ahrq.gov/professionals/quality-patient-safety/patient-safety-resources/resources/vtguide/index.html. Accessed September 19, 2013.
11. Bhalla R, Berger MA, Reissman SH, et al. Improving hospital venous thromboembolism prophylaxis with electronic decision support. J HospMed. 2013;8(3):115-120.
12. Bullock-Palmer RP, Weiss S, Hyman C. Innovative approaches to increase deep vein thrombosis prophylaxis rate resulting in a decrease in hospital-acquired deep vein thrombosis at a tertiary-care teaching hospital. J HospMed. 2008;3 (2):148-155.
13. Kucher N, Koo S, Quiroz R, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med. 2005;352(10): 969-977.
14. Maynard GA, Morris TA, Jenkins IH, et al. Optimizing prevention of hospital-acquired venous thromboembolism (VTE): prospective validation of a VTE risk assessment model. J HospMed. 2010;5 (1):10-18.
15. Attia J, Ray JG, Cook DJ, Douketis J, Ginsberg JS, Geerts WH. Deep vein thrombosis and its prevention in critically ill adults. Arch Intern Med. 2001;161(10):1268-1279.
16. Michigan Hospital Medicine Safety (HMS) Consortium. http://webservices.itcs.umich.edu/drupal/MiHMS/?q=home. Accessed March 16, 2014.
17. American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP®). 2013. http://site.acsnsqip.org/. Accessed September 19, 2013.
18. Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Dis Mon. 2005;51(2-3): 70-78.
19. Guyatt G, Akl EA, Crowther M, et al. Introduction to the 9th edition: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice. Chest. 2012;141(2 suppl):48s-52s.
20. Rothberg MB, Lindenauer PK, LahtiM, Pekow PS, Selker HP. Risk factor model to predict venous thromboembolism in hospitalized medical patients. J HospMed. 2011;6(4):202-209.
21. Umscheid CA, Hanish A, Chittams J, Weiner MG, Hecht TE. Effectiveness of a novel and scalable clinical decision support intervention to improve venous thromboembolism prophylaxis: a quasi-experimental study. BMC Med Inform Decis Mak. 2012;12:92. doi:10.1186/1472-6947-12-92.
22. Johnbull EA, Lau BD, Schneider EB, Streiff MB, Haut ER. No association between hospital-reported perioperative venous thromboembolism prophylaxis and outcome rates in publicly reported data. JAMA Surg. 2014;149(4):400-401.
23. Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW; THE-PRINCE Study Group. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patientswith heart failure or severe respiratory disease. AmHeart J. 2003;145(4):614-621.
24. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ; PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110(7):874-879.
25. Samama MM, Cohen AT, Darmon JY, et al; Prophylaxis in Medical Patients with Enoxaparin Study Group. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med. 1999;341(11):793-800.
26. Kahn SR, LimW, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 suppl):e195Se226S.
27. Maynard GA. Medical admission order sets to improve deep vein thrombosis prevention: a model for others or a prescription for mediocrity? J Hosp Med. 2009;4(2):77-80.
28. Cohen AT, Alikhan R, Arcelus JI, et al. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost. 2005;94(4):750-759.
29. Bilimoria KY, Chung J, Ju MH, et al. Evaluation of surveillance bias and the validity of the venous thromboembolism quality measure. JAMA. 2013; 310(14):1482-1489.
30. Spyropoulos AC, McGinn T, Khorana AA. The use of weighted and scored risk assessment models for venous thromboembolism. Thromb Haemost. 2012;108(6):1072-1076.
31. Bahl V, Hu HM, Henke PK, Wakefield TW, Campbell DA Jr, Caprini JA. A validation study of a retrospective venous thromboembolism risk scoringmethod. Ann Surg. 2010;251(2):344-350.
32. Zakai NA, Wright J, Cushman M. Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score. J Thromb Haemost. 2004;2(12):2156-2161.